Core Viewpoint - The company has entered into a product cooperation agreement with Youer Pharmaceutical Technology (Shanghai) Co., Ltd. to commercialize the world's first epinephrine nasal spray, Neffy® (优敏速®), for emergency treatment of type I allergic reactions in adults and children in China [1][2] Group 1: Product Cooperation and Market Potential - The agreement grants the company exclusive commercialization rights in mainland China and non-exclusive rights in Hong Kong for Neffy®, which is expected to enhance accessibility for severe allergic reaction patients [1][2] - Neffy® is the first non-injection treatment product approved by the FDA for type I allergic reactions in 35 years, filling a gap in emergency medication for out-of-hospital scenarios [2] Group 2: Company’s Strategic Focus - The company is focusing on the cardiovascular emergency sector, which includes both emergency rescue and chronic disease management, with over 30 products in its portfolio [3] - The company has a strong presence in the emergency medication market, with 14 products listed in the national emergency medication catalog and 16 in the shortage medication catalog [3] Group 3: Innovation and Development Strategy - The company emphasizes innovation and advanced technology development, aiming to meet unmet clinical needs and enhance its product pipeline through global innovation [4] - The strategy includes a dual-circulation development model that promotes both domestic and international growth, leveraging the company's industrial advantages and research capabilities [4]
远大医药(00512)引进全球首款用于治疗严重过敏反应的肾上腺素鼻喷雾剂